peloruside-a and Brain-Neoplasms

Microtubule-stabilizing drugs are useful in cancer therapy and show promise for treatment of neurodegenerative diseases. An overlapping binding site between tau and taxoid site drugs has led to a number of research papers investigating the competitive interaction between these drugs and the microtubule. This has implications for cancer treatment since increased tau could confer resistance to paclitaxel. Variations in the tau isoform ratio have also been reported in tauopathies, especially the rise in the levels of the four-repeat tau isoform. Therefore, in conditions of increased or altered expression of tau and its isoforms, a therapy that is not directly affected by changes in tau is desirable. Peloruside A and laulimalide are of particular interest in this respect because of their distinct binding site on the microtubule in relation to the clinically used drugs paclitaxel and ixabepilone. In the present study, we show that peloruside A and laulimalide stabilize microtubules independently of tau overexpression; whereas, the effects of paclitaxel and ixabepilone are masked by the presence of extra tau in the cell.

Topics: Animals; Antineoplastic Agents, Phytogenic; Brain Neoplasms; Bridged Bicyclo Compounds, Heterocyclic; Cell Line, Tumor; Drug Resistance, Neoplasm; Epothilones; HEK293 Cells; Humans; Lactones; Macrolides; Mice; Microtubules; Neuroblastoma; Paclitaxel; Pharmacogenetics; tau Proteins; Tauopathies; Transfection; Tubulin Modulators